The Journal of Virology & Antiviral Research (JVA) promotes rigorous research that makes a significant contribution in advancing knowledge for Microbiology and Medicine. The journal includes all major themes pertaining to viral diseases and treatment.
Virology & Antiviral Research is a subscription based journal that provides a range of options to purchase our articles and also permits unlimited Internet Access to complete journal content. It accepts research, review papers, online letters to the editors & brief comments on previously published articles or other relevant findings in SciTechnol. Articles submitted by authors are evaluated by a group of peer review experts in the field and ensures that the published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate and reliable.
Detection of Rotavirus G3PGenotype in Gnotobiotic Rabbit Model
Rotaviruses have been recognized as important agents of acute diarrhea in both humans and animals. The use of animal models, including the gnotobiotic rabbit, mouse, piglets, lambs and calves models, has been essential to the understanding of rotavirus infection, pathology, disease, immunity, and testing of vaccine prototypes. The aim of this study was to describe the first detection of rotavirus G3P in rabbits in Brazil and to demonstrate the importance of monitoring gnotobiotic animals used in vaccine clinical tests.
Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line
In a study to use a non-pathogenic Simian/Human Immunodeficiency Virus (SHIV) to overcome pathogenic SHIV in a dual infection/competition assay, two SHIVs, pathogenic 89.6P and non-pathogenic NM-3rN, whose replicative fitness were adjusted to be of equal strength, were mixed together and allowed to compete during many transfers in a monkey-derived cell line HSC-F. This is to identify the conditions under which a nonpathogenic SHIV could out-compete a pathogenic SHIV in order to understand the principles underlying evolution of adaptation and selection and to see if the underlying principle could serve as a guide in the design of a therapeutic Human Immunodeficiency Virus (HIV) vaccine.
Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population
Morbidity and mortality rates from chronic liver disease secondary to hepatitis C virus (HCV) have become a significant issue for HIV infected patients. U.S. Department of Health and Human Service guidelines recommend HCV treatment for all coinfected patients without decompensated liver disease. Telaprevir and boceprevir are direct-acting agents (DAAs) recently approved for HCV genotype-1 mono-infection and have demonstrated marked improvements in viral suppression when combined with peg-interferon/ribavirin as triple therapy. Identification of co-infected patients who could benefit from HCV treatment is a necessary component of quality HIV care.